Codexis Inc (CDXS): Market Cap to Revenue Ratio

Symbol and logo of brand Codexis Bio (CDXS)

On GURU.Markets, the P/S divergence from the historical average demonstrates market expectations, where the value of 1.40 serves as the current indicator. The Codexis, Inc. (CDXS) business is exposed to risks due to its dependence on major customers and lengthy development cycles. However, the CodeEvolver platform makes their expertise indispensable, reducing costs for partners. An impeccable reputation as a biocatalysis leader ensures the company maintains the full trust of global pharma behemoths.

CDXS Codexis Bio: Market Cap to Revenue in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Codexis, Inc. (CDXS)

- price and consensus price forecast:
Market Chart codexis.com|CDXS - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Codexis Bio|CDXS - Enterprise Value
- business book valuation details:
Accounting Value per Share Codexis, Inc.|CDXS - Company Net Assets|Market Capitalization to Book Value codexis.com|CDXS - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Codexis, Inc.|CDXS - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio codexis.com|CDXS - Company Total Debt|Debt to Book Value Ratio Codexis Bio|CDXS - Company Long-Term Debt|Short-Term Debt Volume Codexis, Inc.|Immediate Liquidity Ratio codexis.com
- business earnings and investment ratios data:
CDXS - Company Net Income|Net Profit Forecast Codexis, Inc.|CDXS - P/E Multiple|Forward P/E Multiple codexis.com|CDXS - PEG Multiple|Enterprise Value to EBITDA Ratio Codexis Bio|CDXS - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Codexis, Inc.|CDXS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months codexis.com|CDXS - Earnings growth in current year|Expected net earnings per share growth next year Codexis, Inc.
- sales revenue and business income indicators:
CDXS - Company Sales|Company Revenue Forecast codexis.com|CDXS - P/S Multiple|Market Cap to Expected Sales Ratio Codexis Bio
Summary company analytics:Codexis Inc (CDXS)
Original product of Codexis Inc

The P/S multiple determines the market value of one dollar of revenue, allowing for an assessment of the business premium regardless of current earnings. The price-to-sales ratio trend reflects market confidence in the commercialization of the R&D pipeline of Codexis, Inc. (CDXS), where any decline in the indicator may signal decreasing demand for engineered enzymes within the biopharmaceutical sector.

Competitors of Codexis, Inc.

Price-to-Revenue Coefficient Tempus AI|Price-to-Revenue Ratio Qiagen QGEN|IONS: Market Cap to Revenue Ratio|Repligen Corp. - P/S Multiple|Avidity Corp (RNA) - Market Cap to Revenue|CRSP (CRISPR Therapeutics AG) - Market Cap to Revenue|WGS - Price-to-Revenue Coefficient|RARE (Ultragenyx) - P/S Multiple|Market Cap to Revenue Beam Therapeutics Inc (BEAM)|P/S Multiple SRPT|Twist Bioscience Corp - Market Cap to Revenue Ratio|10x Genomics, Inc. - Market Cap to Revenue|NTLA: Market Cap to Revenue Ratio|STOK - Price-to-Revenue Ratio|Price-to-Revenue Coefficient BioLife Solutions Inc BLFS|WVE: P/S Multiple|Market Cap to Revenue Ratio MAZE|Price-to-Revenue Ratio Sionna Therapeutics Inc|Market Cap to Revenue Ratio PRME (primemedicine.com)|P/S Multiple TSHA|P/S Multiple uniQure NV (QURE)|P/S Multiple MGTX (MeiraGTx PLC)|RGNX - Market Cap to Revenue|SLDB - Price-to-Revenue Ratio|Price to Sales ocugen.com|PACB: P/S Multiple|Market Cap to Revenue Ratio BNTC|DSGN (Design Pharma) - P/S Multiple|Price to Sales Rocket Corp RCKT|Market Cap to Revenue FDMT (4D Molecular Therapeutics)|lexeotx.com - Market Cap to Revenue Ratio|P/S Multiple KRRO (Korro Bio)|Price-to-Revenue Coefficient Editas Medicine Inc (EDIT)|SLN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ProQR Therapeutics N.V. PRQR|SGMO (Sangamo Therapeutics) - Market Cap to Revenue|Nautilus Bio - Market Capitalization-to-Revenue Ratio|MGX (Metagenomi) - P/S Multiple|precisionbiosciences.com (DTIL) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Generation Bio Co. (GBIO)|Boundless Bio Inc - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure)|IMNN - Market Cap to Revenue|PHIO: Market Cap to Revenue|Price-to-Revenue Coefficient Mustang Bio, Inc. MBIO|RNAZ: P/S Multiple|Market Cap to Revenue Bionano Genomics|APDN (Applied DNA Sciences) - P/S Multiple|Market Cap to Revenue Ratio BLUE (bluebirdbio.com)|Market Cap to Revenue IPA (ImmunoPrecise Antibodies)|Omega Therapeutics Inc - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|Price-to-Revenue Coefficient Regulus (RGLS)|Syros Pharmaceuticals - P/S Multiple|TBIO (telesisbio.com) - Market Cap to Revenue Ratio|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio UBX